Navigation Links
Helix BioMedix to Discuss Potential of Its Proprietary Peptides at,the BIO International Convention

BOTHELL, Wash., April 18, 2007 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc. today announced that Timothy Falla, Ph.D, Chief Scientific Officer, will present an update on the company's new generation of small molecule peptide (lipohexapeptide) technology at the BIO International Convention. The convention will take place at the Boston Convention & Exhibition Center in Boston, MA from May 6th through 9th. Dr. Falla's presentation is scheduled for Wednesday, May 9th, Room D at 10:00 am.

Dr. Falla's presentation will discuss the company's research on the potential of lipohexapeptides as broad spectrum anti-infectives in the prevention of wound infections caused by multiple-resistant hard to treat pathogens such as Pseudomonas aeruginosa in burns, Staphylococcus aureus in surgical wounds and Acinetobacter baumannii in trauma wounds. The company's lipohexapeptides are designed specifically to overcome the disadvantages that have hampered the industry's previous attempts to develop therapeutic antimicrobial peptides. These 'new generation' peptides are excellent drug candidates due to their low toxicity, attractive cost of goods profile, and evidence of efficacy in both bacterial and fungal infection models.

Helix BioMedix's peptides are also currently bringing value-added performance benefits to the cosmeceutical and personal care markets in the areas of anti-acne and anti-aging skin care. The company believes that an increasing number of industry leaders and skin care clinicians are identifying peptides as the next generation of cosmetic skin care technology and the company's proprietary peptides are being incorporated into a growing number of products through various licensing agreements.

Helix BioMedix will be participating in the BIO Business Forum Partnering Program. In 2007, Helix BioMedix has plans to accelerate its entry into the arena of pharmaceutical topical anti-infectives with a focus on the large anti-infective dermatology market, including indications such as acne and dermatitis. The company also hopes to increase the number of peptide-enhanced personal care products that contain Helix BioMedix peptides in the next several years.

The Biotechnology Industry Organization (BIO), founded in 1993, is a nonprofit association that represents more than 1,100 biotechnology companies, state and international affiliates, and related organizations. BIO is widely known for the BIO International Convention, a four-day annual biotechnology showcase that draws about 20,000 attendees. The convention serves to educate the public and policymakers about biotechnology, while fostering partnering meetings and other business development activities that keep the industry growing.

About Helix BioMedix

Helix BioMedix, Inc. is a biopharmaceutical company with a vast library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. The company's mission is to enrich clinical practice and the patient and consumer experience by expanding opportunities to tap the health, beauty and safety benefits of advanced bioactive small molecule technology. Its vision is to be recognized as the world leader in the identification, qualification and commercialization of natural and synthetic peptide technology.

The company's core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology. These areas of expertise are leveraged through relationships with contract research organizations and peptide manufacturers for the capability to take a program from theoretical concept to a validated and qualified skin care active with respect to both efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care, acne treatment and other topical anti-infective pharmaceuticals and w ound healing. In addition to our primary focus on peptides for dermatological applications, the company's peptide library also holds promise for advancements in other therapeutic and industrial areas such as oral care, biocides and animal health.

More information about the company and its proprietary peptides may be found on the company's website at .

Important Notice

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to our potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in our reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.


    Investor Relations:

    Cameron Associates

    Alison Zieg
ler, 212-554-5469

CONTACT: investors, Alison Ziegler of Cameron Associates, +1-212-554-5469,, for Helix BioMedix, Inc.

Web site:

Ticker Symbol: (NASDAQ-OTCBB:HXBM)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
2. Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
5. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
6. Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed
7. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. New Information on the Potential of Plasmin Shared at ISTH Congress
10. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
(Date:12/2/2015)... 2015 TB Alliance and its partners ... medicines in the correct doses. The improved treatments ... set by the World Health Organization (WHO) in ... administer and affordable. The availability of these products ... by UNITAID. ...
(Date:12/1/2015)... and VANCOUVER , Dec. 1, 2015 ... OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today ... on the pre-planned interim futility analysis of the intent-to-treat ... safety issues were identified by the DMC. Both the ... final results are expected in the second half of ...
(Date:12/1/2015)... 01, 2015 ... the "Spinal Muscular Atrophy Market - ... 2015 - 2023" report to their ... announced the addition of the "Spinal ... Growth, Trends, and Forecast 2015 - 2023" ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... According to an article published on ... claim against the U.S. Department of Health and Human Services, claiming that any states ... are breaking the clause in the law prohibiting the denial of coverage for pre-existing ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... there are professionals who believe that with innovative technologies and under the right ... patient to get the benefit of a dual-approach to his or her therapeutic ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo ... — a number even greater among Millennials (a whopping one in three aged 18 ... more people who are dissatisfied with their ink. In fact, RealSelf , the ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic ... addition to the devices for sale in the United States. Clarity is a ... 1064 nm Nd:YAG lasers, into a single platform that is easy to own and ...
Breaking Medicine News(10 mins):